| INTRODUCTION
Coronary heart disease is a leading cause of morbidity and mortality worldwide.
1 Treatment options include coronary artery bypass surgery and balloon angioplasty combined with stent implantation 2 ; however, the failure rate for treatment is high (8%-40%) because of restenosis (recurrence of blood vessel narrowing) predominantly caused by intimal hyperplasia. [3] [4] [5] [6] Intimal hyperplasia is the thickening of a blood vessel wall in response to injury, potentially induced by a surgical procedure. Mesenchymal stem cells (MSCs) have been shown to exert an inhibitory effect on neointimal hyperplasia (the new layer of arterial intima formed particularly on a prosthesis) via rapid re-endothelialisation. 7 Another study reported the therapeutic effects of human MSCs by decreasing the inflammatory response to carotid artery ligation. 8 Exosomes secreted by MSCs have been shown to mediate intercellular communications between these cells and their target cells 9 ; however, the role of MSC-derived exosomes (MSC-Exo) in neointimal hyperplasia remains to be fully elucidated.
Exosomes, small membraned vesicles (30-100 nm) that are generated through inward budding of the endosomal membrane, modulate the function of recipient cells by transferring complex biological information, including mRNAs, microRNAs (miRNAs) and soluble proteins into these target cells in a functional form. [10] [11] [12] Liang et al showed that transfer of miR-125a to endothelial cells via MSC-Exo promoted angiogenesis in these target cells by miR-125a-mediated repression of DLL4. 9 The direct effect of exosomes on target cell function provides a wide range of potential therapeutic applications, including cellular renewal and tissue repair following myocardial ischaemia-reperfusion, 13 neurological stroke 14 and skin wounds, 15 likely mediated by mechanisms involving exosome-transferred miRNAs. 16, 17 However, whether exosome-mediated miRNA transfer plays a role in neointimal hyperplasia remains poorly understood.
In this study, to evaluate MSC-Exo, and more specifically MSCExo-derived miRNA transfer on neointimal hyperplasia, we assessed their effects on the proliferation and migration of vascular smooth muscle cells (VSMCs) in vitro and in vivo by the determination of neointima formation following balloon-induced vascular injury. Previous studies in VSMCs have reported a number of key miRNAs (miR-21, miR-143, miR-145 and miR-221) that play important roles in proliferation, migration and neointimal thickening. [18] [19] [20] [21] Another key miRNA, miR-125b, has been shown to inhibit the process of calcification of VSMCs, a pathology linked to the development of cardiovascular disease, 22 by inhibiting osteoblastic differentiation and proliferation. [23] [24] [25] In our study, the delivery of miR-125b into VSMCs via MSC-Exo was investigated along with the potential role of MSCExo-transferred miR-125b in neointimal hyperplasia.
Myosin-1E (Myo1e) is an actin-dependent molecular motor whose translocation is essential for lamellipodium extension and subsequent cellular motility and cell migration. 26 Heim et al 27 reported that
Myo1e binds to the FERM domain of focal adhesion kinase (FAK), activating FAK and inducing Y397 phosphorylation. Previous studies revealed that FAK is involved in the regulation of aortic smooth muscle cell motility and growth, and the regulation of smooth muscle cell recruitment during blood vessel morphogenesis. [28] [29] [30] The potential role of Myo1e and FAK activation in VSMCs in response to MSC-Exoderived signals was also investigated in this study. Our findings provide insight into the role of MSC-Exo-mediated miR-125b transfer on neointimal hyperplasia following arterial injury, offering potential therapeutic targets for vascular diseases.
| ME TH ODS

| Cell culture
Bone marrow MSCs were isolated as previously described. 31 Briefly, total bone marrow cells were flushed from the femurs and tibias of Sprague-Dawley rats using culture media. The cells were then cultured in DMEM/F12 (HyClone, Logan, UT, USA), supplemented with 10% FBS (Gibco, Carlsbad, CA, USA) at 37°C in a humidified incubator containing 5% CO 2 . After 48 hours, nonadherent cells were removed by aspirating the media and replacing with fresh media.
MSCs of passages 3 to 5 were used for subsequent experiments.
MSCs (passage 3) were identified by flow cytometry with antibodies against phycoerythrin (PE)-CD90, PE-CD29, fluorescein isothiocyanate (FITC)-CD44 and FITC-CD34 (BD Biosciences, Franklin Lakes, NJ, USA). The analysis was performed with a FACSCalibur flow cytometer (BD Biosciences).
Primary rat VSMCs were isolated as previously described 32 with some modifications. Briefly, the aorta of an adult Sprague-Dawley rat was excised, cleaned of connective tissue, fat and endothelium and cut into 1-mm 2 pieces. The pieces were treated with 1 mL (1 mg/mL) of collagenase II (Sigma-Aldrich, St. Louis, MO, USA) and 0.125% trypsin for 1 hour at 37°C, followed by centrifugation at 300 g for 5 minutes to harvest the cells. Cells were cultured in DMEM supplemented with 10% FBS, and passages 3-7 were used for subsequent experiments. HEK293 cells were cultured in DMEM containing 10% FBS.
| Cell transfection
For miR-125b overexpression, primary MSCs isolated from rats were transfected with mimic control (NC) or miR-125b mimic (50 nmol/L; GenePharma, Shanghai, China), and for miR-125b knockdown, primary MSCs from rats were transfected with an inhibitor control (IC)
or miR-125b inhibitor (100 nmol/L; GenePharma) using Lipofec- and cells were transfected as described above. For Myo1e knockdown, vector GV112 plasmids carrying shRNA for Myo1e (target sequence: 5′-GCATCAACCGAAACTTCATCG-3′) or control shRNA were purchased from the GeneChem corporation (Shanghai, China).
Cells were transfected with either shRNA plasmids for Myo1e or for control as described above.
| Isolation and characterisation of exosomes
To isolate the exosomes of MSCs, the cells were cultured in DMEM/ F12 containing 10% exosome-free FBS for 48 hours and the supernatants were collected and centrifuged at 3000 g for 15 minutes to remove the cells and cell debris. The exosomes were isolated from the supernatants using ExoQuick-TC Kit (System Biosciences, Mountain View, CA, USA) according to the manufacturer's instructions. The pelleted exosomes were fixed in 2% paraformaldehyde in PBS, pH 7.4 and the morphology of the exosomes was observed using transmission electron microscopy (TEM) as previously described. 33 The exosomes were further characterized by Western blot analysis with three exosome-specific biomarkers: CD9, CD63 and CD81 (Abcam, Cambridge, UK). 
| Internalisation of DIO-labelled exosomes into VSMCs
| Cell proliferation assay
| In vivo effects of MSC-Exo in a rat model of balloon-induced vascular injury
The balloon-induced vascular injury model was performed as previously described. 34 Briefly, Sprague-Dawley rats weighing 250-300 g (SLAC Laboratory Animal Co., Ltd, Shanghai, China) were anes- 
| Histomorphometry and immunofluorescence
For histomorphometry and immunofluorescence analysis, excised arteries were fixed in 4% paraformaldehyde for 24 hours, dehydrated, 
| Statistical analysis
Data are expressed as the mean ± SD. Statistical significance was determined by an unpaired Student's t test or one-way ANOVA with the Bonferroni post-hoc test using GraphPad Prism 5.0 software. The results of all of the in vitro experiments are representative of at least three separate experiments conducted in triplicate and P < 0.05 was considered to indicate a statistically significant difference.
| RESULTS
| MSC-Exo reduce VSMC proliferation and migration
The establishment of an MSC culture was confirmed visually by the presence of elongated and linear cells and by flow cytometry with antibodies directed against CD90, CD29, CD44 and CD34
( Figure 1A,B) . To evaluate the effects of MSC-Exo on neointimal hyperplasia, MSC-Exo were isolated and the morphology of the exosomes was observed using TEM. The exosomes purified from the MSC culture supernatants were round membrane-bound vesicles that were~50-100 nm in diameter ( Figure 1C ). Then, Western blot analysis was performed on the proteins from MSC lysates and purified exosomes to confirm the presence of exosome/extracellular vesicle-specific markers: CD63, CD81 and CD9. As expected, all three markers were strongly expressed in the purified exosomes ( Figure 1D ). Next, VSMCs were incubated with DIO-labelled exosomes and confocal microscopy was performed to demonstrate the internalisation of DIO-labelled exo- indicating that the presence of MSC-Exo also had a suppressive effect on VSMC migration.
| MSC-Exo deliver miR-125b into VSMCs
To investigate the MSC-Exo-mediated transfer of the miRNA, miR125b, into VSMCs, the relative expression levels of miR-125b in
MSCs and MSC-Exo were first determined by quantitative reversetranscription PCR (RT-qPCR). Expression levels of miR-125b were significantly higher in MSC-Exo than in MSCs (P < 0.05; Figure 2A ). Next, the expression of miR-125b in VSMCs after incubation with MSC-Exo was determined by RT-qPCR and significantly higher miR-125b expression was detected in VSMCs incubated with MSC-Exo compared with control VSMCs (P < 0.05; Figure 2B ). To demonstrate the transfer of miRNA from MSCs into VSMCs via exosomes, exosomes were isolated from MSCs transfected with Cy3-miR-125b for 48 hours and were then incubated with VSMCs for 3 hours. Localisation of Cy3-miR-125b (red) in the exosome-treated VSMCs (counterstained with DAPI, blue) was observed using a confocal microscope ( Figure 2C ). This provided evidence for the exosome-mediated transfer of miR-125b from MSCs into VSMCs. Figure 3C ). Conversely, VSMC proliferation was increased following treatment with exosomes from
MSCs transfected with miR-125b inhibitor compared with exosomes from IC-transfected MSCs (P < 0.05; Figure 3D ).
Next, the effects of MSC-derived exosomally transferred miR125b on VSMC migration were assessed using the same MSC transfected strains and a scratch-wound assay. VSMC migration was decreased following treatment with exosomes from MSCs transfected with miR-125b mimic compared with exosomes from NC-transfected MSCs (P < 0.05; Figure 3E ). Conversely, VSMC migration was increased following treatment with exosomes from
MSCs transfected with miR-125b inhibitor compared with exosomes from IC-transfected MSCs (P < 0.05; Figure 3F ). Taken together, these findings indicate that miR-125b delivered by MSC-Exo inhibits VSMC proliferation and migration.
| Exosomal miR-125b suppresses VSMC proliferation and migration by targeting Myo1e
Next, the mechanism responsible for exosomal miR-125b-mediated suppression of VSMC proliferation and migration was investigated. A miR-125b binding site was identified in the 3ʹUTR of rat Myo1e
( Figure 4A ). Myo1e is an actin-dependent molecular motor previously reported to play a role in lamellipodium extension and subsequent cell migration. 26 A dual luciferase assay was therefore performed with WT and mutant (MUT) constructs of the Myo1e 3′
UTR in VSMCs transfected with miR-125b mimic or inhibitor (Figure 4B) . Transcription of the 3ʹUTR of WT Myo1e, as indicated by luciferase activity, was significantly decreased in VSMCs transfected with miR-125b mimic compared with the NC (P < 0.01), and significantly increased in VSMCs transfected with miR-125b inhibitor compared with the IC (P < 0.05). These effects were abolished when the MUT 3ʹUTR construct was used, indicating the specific interaction between miR-125b and the 3ʹUTR of rat Myo1e.
To further confirm the effect of miR-125b on Myo1e expression, RT-qPCR analysis of Myo1e expression was performed on VSMCs ( Figure 4C ). As expected, in the presence of PDGF-BB, Myo1e
F I G U R E 2 Mesenchymal stem cells (MSC)-derived exosomes delivered miR-125b into vascular smooth muscle cells (VSMCs). (A) Relative expression levels of miR-125b in MSCs and MSC-derived exosomes as determined by RT-qPCR. Three independent experiments (n = 3). (B)
Expression levels of miR-125b in VSMCs with and without treatment with exosomes as determined by RT-qPCR. *P < 0.05 vs untreated cells.
Three independent experiments (n = 3). (C) Exosomes were isolated from MSCs transfected with Cy3-miR-125b for 48 h and incubated with
VSMCs for 3 h. Localisation of Cy3-miR-125b (red) in the exosome-treated VSMCs was observed using a confocal microscope. Nuclear counterstaining was performed with DAPI (blue) Experiments were repeated at least three times (n = 3) and data are the average of repeat experiments. *P < 0.05, **P < 0.01
Focal adhesion kinase has been reported to play a role in the proliferation and migration of aortic smooth muscle cells, and the regulation of smooth muscle cell recruitment during blood vessel morphogenesis. [28] [29] [30] Myo1e has previously been reported to induce FAK phosphorylation and FAK kinase activity. 27 Here, the phosphorylation of FAK was examined by Western blot analysis in the VSMCs after the indicated treatment ( Figure 4H ). 
| miR-125b delivered by MSC-Exo reduces neointima formation in rat carotid arteries after angioplasty
To analyse the effects of exosome-derived miR-125b on neointima Several studies have recognized miR-125b as an important mediator for the modulation of the SMC phenotype. 23, 25, 51 Deregulation of VSMC phenotype switching is associated with vascular proliferative and migration disorders. 52 Through literature searches, we found that miR-125b was enriched in MSC-Exo, 53 ,54 therefore, we investigated the role of MSCExo-mediated miR-125b transfer on neointimal hyperplasia following arterial injury. The findings from our study indicated that MSC-Exo are enriched in miR-125b and can transfer this miRNA to VSMCs. In previous studies, miR-125b was reported to play a role in osteoblast differentiation by regulating cell proliferation, 23 and osteogenic transdifferentiation of VSMCs and the proliferation of human coronary artery smooth muscle cells. 25 In our study, we demonstrated that miR-125b targets the 3ʹUTR of Myo1e in VSMCs repressing its expression and affecting subsequent FAK activation.
The interaction between Myo1e and FAK and the resulting phosphorylation-activation of FAK has been shown to be crucial for cell motility, 27, 28 and therefore the transcriptional repression of Myo1e would be expected to inhibit the migratory behaviour of VSMCs.
Myosin 1E is an actin-dependent molecular motor that is expressed in a range of tissues and has the ability to bind to both cell membranes and actin filaments. Myo1e also binds phospholipids with high affinity 55 and regulates podocyte function and glomerular filtration. 56 Furthermore, the ERK-mediated translocation of Myo1e from the cytosol to the tips of lamellipodia is essential for cell motility and migration 57 and Myo1e regulates TLR4-triggered macrophage spreading and chemokine release as part of the innate immune response.
58
Myo1e has therefore been linked to a number of diseases such as atherosclerosis, 59 coronary artery disease and kidney disease. 60 In our study, using a rat model of balloon-induced vascular injury, we revealed that exosome-derived miR-125b repressed Myo1e expression, suppressed VSMC proliferation and migration and inhibited neointima formation in rat carotid arteries following angioplasty.
Our findings suggest that miR-125b may be a potential therapeutic candidate for the treatment of vascular diseases and arterial injury. It is conceivable that this miRNA could be delivered to the site of injury by incorporation into a drug-eluting stent.
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